Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.

Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA.

Am J Cardiol. 1997 Dec 15;80(12):1613-5.

PMID:
9416950
2.

A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).

Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R; MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).

Clin Ther. 2002 Jan;24(1):126-38.

PMID:
11833827
4.
5.

Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.

Chiou KR, Chen CH, Ding PY, Chen YT, Ting CT, Huang JL, Chiang AH, Liu CP, Tseng CJ, Chao CT, Chang MS.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 May;63(5):368-76.

PMID:
10862446
6.

Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.

Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M.

J Hypertens. 1998 Mar;16(3):385-93.

PMID:
9557932
9.

An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.

Byyny RL, Merrill DD, Bradstreet TE, Sweet CS.

Cardiovasc Drugs Ther. 1996 Jul;10(3):313-9.

PMID:
8877074
10.

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.

Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J, Witcher JA.

Clin Ther. 1998 May-Jun;20(3):398-409.

PMID:
9663357
11.
12.

The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.

Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, Remuzzi G.

J Am Soc Nephrol. 1998 Dec;9(12):2308-17.

13.

Antihypertensive effects of candesartan cilexetil, enalapril and placebo.

Franke H.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S61-2. No abstract available.

PMID:
9331010
14.
15.

Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.

Stumpe KO, Haworth D, Hoglund C, Kerwin L, Martin A, Simon T, Masson C, Kassler-Taub K, Osbakken M.

Blood Press. 1998 Jan;7(1):31-7.

PMID:
9551875
16.

Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.

Ogihara T, Arakawa K.

J Hum Hypertens. 1999 Jan;13 Suppl 1:S27-31; discussion S33-4. Review.

PMID:
10076918
17.

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.

Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E.

Am J Hypertens. 1998 Apr;11(4 Pt 1):445-53. Erratum in: Am J Hypertens 1998 Jun;11(6 Pt 1):736.

PMID:
9607383
18.

Irbesartan treatment in hypertension.

Brown MJ.

Hosp Med. 1998 Oct;59(10):808-11. Review.

PMID:
9850301
19.
20.

Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.

von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG.

Eur J Pediatr. 2000 Aug;159(8):590-3.

PMID:
10968237

Supplemental Content

Support Center